Ultime notizie per Canada Goose Hldgs (NYSE:GOOS) Azioni

Canada Goose Hldgs

Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of functional and fashionable retailers, including major luxury department stores, outdoor specialty stores, individual shops, and international distributors. Geographically, it has a presence in Canada, the United States, Asia, Europe, and the Rest of the World.

Canada Goose Holdings Inc. Subordinate Voting Shares

Canada Goose Holdings Inc

Goose Hollow Tactical Allocation ETF

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance Inc

WIIM

SRPT

Sarepta Therapeutics shares are trading higher after the company provided dosing updates on its ENVISION study of ELEVIDYS.

Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) reported quarterly earnings of $18.98 per share. This is a 114.02 percent increase over losses of $(135.37) per share from the same period last year. The company reported $1.11 million in sales this quarter. This is a 42.75 percent decrease over sales of $1.94 million the same period last year.

Earnings

News

RSLS

Reshape Lifesciences Q1 EPS $18.98 Up From $(135.37) YoY, Sales $1.11M Down From $1.94M YoY

Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) reported quarterly earnings of $1.41 per share. This is a 105.13 percent increase over losses of $(27.48) per share from the same period last year. The company reported $4.40 million in sales this quarter. This is a 20.42 percent decrease over sales of $5.53 million the same period last year.

DGLY

Digital Ally Q1 EPS $1.41 Up From $(27.48) YoY, Sales $4.4M Down From $5.53M YoY

Guggenheim analyst Steven Forbes reiterates Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Buy and maintains $450 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Home Depot, Maintains $450 Price Target

Garrett Motion shares are trading lower after the company announced a secondary offering consisting of 17 million shares.

Jefferies analyst David Chiaverini initiates coverage on Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Hold rating and announces Price Target of $10.

Initiation

Jefferies Initiates Coverage On Valley Ntl with Hold Rating, Announces Price Target of $10

Dycom Industries shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY26 sales guidance.

ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) reported quarterly losses of $(0.08) per share. This is a 11.11 percent increase over losses of $(0.09) per share from the same period last year. The company reported $6.42 million in sales this quarter. This is a 8.13 percent decrease over sales of $6.99 million the same period last year.

ECDA

ECD Automotive Design Q1 EPS $(0.08) Up From $(0.09) YoY, Sales $6.42M Down From $6.99M YoY

Guggenheim analyst John Difucci reiterates SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy and maintains $28 price target.

Guggenheim Reiterates Buy on SentinelOne, Maintains $28 Price Target

Jefferies analyst David Chiaverini initiates coverage on Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Hold rating and announces Price Target of $80.

TCBI

Jefferies Initiates Coverage On Texas Capital Bancshares with Hold Rating, Announces Price Target of $80

James Hardie Industries shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Full Truck Alliance shares are trading lower. The company reported Q1 financial results.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he doesn't like ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), adding that &#8220;<a href="https://www.benzinga.com/quote/ZIM/earnings">dividend is a sucker's play.&#8221;</a>
On the earnings front, the company posted quarterly earnings of $2.45 per share on May 19, beating the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $2.01 billion, also beating the analyst consensus estimate of $1.85 billion.
Cramer recommended not buying The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) because the stock is up too much. &#8220;A parabolic move. If I come in now, I think I am too late,&#8221; he added.
On May 6, Mosaic reported quarterly earnings of 49 cents per share, which beat the analyst consensus estimate of 45 cents per share. The company reported quarterly sales of $2.62 billion, which missed the analyst consensus estimate of $2.66 billion.
&#8220;It does seem to be dead money,&#8221; Cramer said when asked about Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>). &#8220;I don't see much happening in the veterinary or livestock market at this very moment that's going to help them.&#8221;
As per recent news, the animal health firm reported a first-quarter 2025 adjusted EPS of $1.48 on May 6, up from $1.38 a year ago and beating the consensus of $1.39.
Price Action:
<ul class="wp-block-list">
<li>ZIM shares fell 2.7% to settle at $18.85 on Tuesday.</li>
<li>Mosaic shares rose 0.5% to close at $35.53 during the session.</li>
<li>Zoetis shares fell 0.2% to settle at $163.65 on Tuesday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Media

Jim Cramer Recommends Not Buying Mosaic, Doesn't Like This Industrial Stock

Mortgage rates have jumped to their highest level in three months as U.S. Treasury yields, driven by rising deficits and fiscal policy fears, push the 30-year benchmark <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45505333/investors-piled-into-long-term-treasury-etfs-ahead-of-moodys-downgrade-will-confidence-hold">above the critical 5% mark</a>.
According to the latest Mortgage Bankers Association report, mortgage application volumes in the U.S. dropped 5.1% for the week ending May 16, the steepest decline in a month.
The drop coincided with the 30-year fixed mortgage rate jumping 6 basis points to 6.92%, marking its highest level in three months.
The rise in borrowing costs tracked Treasury yields higher &#8220;with investors concerned about rising inflation and the impact of increasing deficits and debt", said Mike Fratantoni, MBA's chief economist.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45537307/us-stocks-likely-to-open-lower-expert-says-tariffs-remain-a-headwind-but-tax-cut-and-easing-of-tensions-in-middle-east-could-propel-equities-closer-to-all-time-highs">US Stocks Likely To Open Lower, Expert Says &#8216;Tariffs Remain A Headwind&#8217;</a>
<h3 class="wp-block-heading">Why Are Treasury Yields Rising?</h3>
Yields on the 30-year Treasury bond soared to 5.02% on Wednesday, up by over 10 basis points from a week ago.
A recent downgrade by Moody's of U.S. sovereign debt after market close last Friday has added to the pressure, shaking investor confidence and pushing yields higher. 
Bondholders are pricing in higher risk premiums as the federal government accelerates deficit spending without clear offsetting revenue measures.
A new tax-and-spending bill backed by President Donald Trump and Republicans is adding fuel to bond market fears. According to the Tax Foundation, the legislation would reduce federal revenues by an estimated $4.1 trillion from 2025 to 2034.
With public debt nearing 100% of gross domestic product and the Congressional Budget Office projecting a 117% debt-to-GDP ratio by 2035, bond investors are beginning to push back, demanding higher compensation for holding U.S. Treasuries.
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) is down 0.9% during Wednesday premarket trading in New York.
The world&#8217;s biggest bond fund has lost 9% since Trump won the elections in November 2024. 
<h3 class="wp-block-heading">Ed Yardeni Sounds The Alarm On Deficit Risks</h3>
Veteran market strategist Ed Yardeni, founder of Yardeni Research, sounded the alarm over the soaring U.S. budget deficit. 
"Budget deficits matter. That's especially so when they lead to higher interest rates, higher bond yields, and potentially higher inflation," Yardeni said in a note Wednesday. 
Yardeni highlighted that the bond market is reacting not just to headline deficits, but to the structure of the Trump&#8217;s fiscal plan.
&#8220;Trump 2.0&#8217;s tax and spending bill—now moving swiftly through Congress—packs a fiscal punch,&#8221; he added. 
While the bill includes new deductions and credits for lower-income families, the largest benefits accrue to middle-class households via broader standard deductions and lower tax rates. High-income earners see a mixed outcome, with gains offset by reduced exemptions.
Yet Yardeni said every household could feel the pinch if the tax bill drives up fiscal stress, interest rates and borrowing costs.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45537306/google-unveils-total-reimagining-of-search-with-chatbot-style-feature-to-compete-with-openai">Google Unveils Total Reimagining Of Search With Chat-Bot Style Feature</a></li>
</ul>
Image: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Bonds

Treasuries

Econ #s

Economics

Real Estate

iShares Trust Barclays 20+ Year Treasury Bond Fund

5% Treasury Yields Are Back, And So Are Painful Mortgage Rates

UnitedHealth Group shares are trading lower after HSBC downgraded the stock from Hold to Reduce and cut its price target from $490 to $270.

Guggenheim analyst John Difucci reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Sell and maintains $130 price target.

PANW

Guggenheim Reiterates Sell on Palo Alto Networks, Maintains $130 Price Target

Management

MKTX

MarketAxess Holdings Appoints Dean Berry As Group COO And CEO Of EMEA & APAC

General

Conduit Pharmaceuticals Regains Nasdaq Compliance

Palo Alto Networks shares are trading lower following Q3 reported financial results. Additionally, Bernstein cut its price target on the stock from $29 to $25.

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy.
We have received feedback from the Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. ENVISION is a global, randomized, double-blind, placebo-controlled Phase 3 study of ELEVIDYS in non-ambulatory and older ambulatory individuals with Duchenne.
About ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age.
<ul>
<li>For patients who are ambulatory and have a confirmed mutation in the DMD gene</li>
<li>For patients who are non-ambulatory and have a confirmed mutation in the DMD gene.</li>
</ul>
The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Biotech

Sarepta Provides Update On UK Dosing in ENVISION Study Of ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy. Company Received Feedback From The Medicines And Healthcare Products Regulatory Agency In U.K That Dosing May Continue Uninterrupted In Envision, Study Srp-9001-303

Press Releases

Canada Goose Announces Renewal of Normal Course Issuer Bid

Haider Ackermann Releases His First 'Snow Goose by Canada Goose' Capsule Collection

Canada Goose to Announce Third Quarter Fiscal Year 2025 Financial Results on February 6, 2025

The Next Moncler? How Emerging Brand Perfect Moment Is Capitalizing On The Luxury Skiwear Market

Canada Goose Announces Renewal of Regulatory Relief Regarding Share Repurchase Program

Canada Goose Strengthens Executive Team with SVP of Merchandising, Judit Bankus

Canada Goose Reports Third Quarter Fiscal 2025 Results

Canada Goose Announces Participation in 46th Raymond James Institutional Investor Conference

Canada Goose to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on May 21, 2025

Canada Goose Reports Fourth Quarter and Full Year Fiscal 2025 Results

GOOS

LULU

MONRF

PMNT

TSX:GOOS

Barclays

Evercore ISI Group

Goldman Sachs

Wells Fargo

Screenshot 2025-03-26 at 5.40.13 PM

Emerging Markets

Movers & Shakers

Perfect Moment Bolsters Leadership With Top Execs From Rival Canada Goose: What Could The Future Hold?

Screenshot 2025-01-21 at 6.29.45 PM

Markets

Canada Goose shares are trading higher following better-than-expected Q4 financial results.

Comments

Canada Goose Hldgs

Notizie

Ultime notizie per Canada Goose Hldgs (NYSE:GOOS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO